Levodopa/Carbidopa/Entacapona Teva-Ratiopharm

Levodopa/Carbidopa/Entacapone, the active ingredient in Levodopa/Carbidopa/Entacapone Teva‑Ratiopharm, is an antiparkinson agent (dopamine precursor and COMT inhibitor combination) presented as an oral tablet for oral use. It treats Parkinson's disease in adults.

GNH USA supplies Levodopa/Carbidopa/Entacapone Teva‑Ratiopharm as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Levodopa/Carbidopa/Entacapone is used within the antiparkinson therapeutic pathway to improve motor control in Parkinson's disease. - Parkinson's disease (early stage): reduces motor symptoms and improves daily functioning. - Parkinson's disease (advanced stage): enhances response to levodopa and lessens wearing‑off phenomena. - Parkinson's disease (off episodes): decreases the duration and frequency of off periods.

Levodopa/Carbidopa/Entacapone may cause a range of adverse reactions.

Common Side Effects: - Nausea - Vomiting - Dizziness or light‑headedness - Orthostatic hypotension - Headache - Insomnia

Serious or Rare Side Effects: - Dyskinesia (involuntary movements) - Hallucinations or psychosis - Severe hypotension or syncope - Cardiac arrhythmias - Neuroleptic malignant syndrome - Anaphylaxis or severe allergic reactions

When prescribing Levodopa/Carbidopa/Entacapone, clinicians should consider several safety aspects. - Renal impairment: assess renal function and adjust therapy if needed. - Hepatic impairment: use with caution; monitor liver enzymes. - Cardiovascular disease: monitor blood pressure for orthostatic changes. - Psychiatric history: watch for hallucinations or confusion. - Concomitant MAO‑B inhibitors: avoid combined use due to hypertensive risk. - Pregnancy: safety unknown; avoid unless benefits outweigh risks. - Store at ambient temperature: keep in original container, protect from moisture and light.

Levodopa/Carbidopa/Entacapone interacts with several drug classes.

Major Interactions (Avoid): - Non‑selective MAO inhibitors: risk hypertensive crisis. - Anticholinergic agents: may mask Parkinsonian symptoms. - Typical antipsychotics (e.g., haloperidol): reduce dopaminergic efficacy.

Moderate Interactions (Monitor Closely): - Antihypertensive drugs: additive hypotensive effect. - SSRIs or SNRIs: potential for serotonin syndrome. - Iron or calcium supplements: decrease levodopa absorption; separate dosing by at least 2 hours.